Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

First-line Therapy With EGFR-TKI Combined With Trastuzumab Rezetecan for Advanced NSCLC Harboring EGFR Mutations Concomitant With HER2 Alterations

NCT07699952 is registered in ClinicalTrials.gov with Yongsheng Wang as lead sponsor.

NCT NCT07699952
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07699952 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
First-line Therapy With EGFR-TKI Combined With Trastuzumab Rezetecan for Advanced NSCLC Harboring EGFR Mutations Concomitant With HER2 Alterations
Lead sponsor
Yongsheng Wang
Phase
Phase 2
Overall status
Not yet recruiting
Start date
September 9, 2026
Completion date
March 31, 2029
Enrollment
35 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

egfr activating mutation, her2, lung cancer (nsclc)